Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Deisseroth

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2008
Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cellsHakan Akbulut, Yucheng Tang, K Gonca Akbulut, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 15, 2018
Determination of Similarity Margin in Comparative Clinical Studies to Support the Development of Biosimilar Products of Neupogen<sup>®</sup> (Filgrastim, Granulocyte Colony-Stimulating Factor [G-CSF])Lei Nie, Donna Przepiorka, Albert Deisseroth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasmsHakan Akbulut, Yucheng Tang, Jonathan Maynard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2013
Gemtuzumab ozogamicinDonna Przepiorka, Albert Deisseroth, Robert Kane, et al.
Molecular Cancer Therapeutics|August 25, 2006
Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancerHakan Akbulut, Yucheng Tang, K Gonca Akbulut, et al.
Blood|July 9, 2004
Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigensYucheng Tang, Lixin Zhang, Jing Yuan, et al.
Blood|January 16, 2010
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemiaAlbert Deisseroth, Ann Farrell, Robert Justice, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2002
Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanomaLixin Zhang, Hakan Akbulut, Yucheng Tang, et al.
Human Pathology|April 21, 2007
Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cellsDe Jun Sun, Ying Liu, Dong Cheng Lu, et al.
The Oncologist|April 26, 2019
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular RemissionE Dianne Pulte, Tanya Wroblewski, Erik Bloomquist, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2008
Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cellsHakan Akbulut, Yucheng Tang, K Gonca Akbulut, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 15, 2018
Determination of Similarity Margin in Comparative Clinical Studies to Support the Development of Biosimilar Products of Neupogen<sup>®</sup> (Filgrastim, Granulocyte Colony-Stimulating Factor [G-CSF])Lei Nie, Donna Przepiorka, Albert Deisseroth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasmsHakan Akbulut, Yucheng Tang, Jonathan Maynard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2013
Gemtuzumab ozogamicinDonna Przepiorka, Albert Deisseroth, Robert Kane, et al.
Molecular Cancer Therapeutics|August 25, 2006
Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancerHakan Akbulut, Yucheng Tang, K Gonca Akbulut, et al.
Blood|July 9, 2004
Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigensYucheng Tang, Lixin Zhang, Jing Yuan, et al.
Blood|January 16, 2010
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemiaAlbert Deisseroth, Ann Farrell, Robert Justice, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2002
Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanomaLixin Zhang, Hakan Akbulut, Yucheng Tang, et al.
Human Pathology|April 21, 2007
Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cellsDe Jun Sun, Ying Liu, Dong Cheng Lu, et al.
The Oncologist|April 26, 2019
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular RemissionE Dianne Pulte, Tanya Wroblewski, Erik Bloomquist, et al.
Pageof 4